Tag: SMA therapies market research

Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Is The Current Size And Growth Outlook For The Spinal Muscular Atrophy Market?

The size of the spinal muscular atrophy market has been rapidly expanding in the past few years. The expected growth is from $3.53 billion in 2024 to around $4 billion in 2025, with a compound annual growth rate (CAGR) of 13.3%. This significant growth in the historical period is due to factors such as enhanced diagnosis and earlier detection, a rising occurrence of rare genetic diseases, advancements in healthcare infrastructure, government and regulatory backing, and an increase in unaddressed healthcare needs.

Anticipations are high for a swift expansion in the spinal muscular atrophy market in the upcoming years. The market is predicted to escalate to a value of $6.53 billion by 2029, with a compound annual growth rate (CAGR) of 13.0%. The enhancement during the projected period can be accredited to the proliferation in awareness and diagnosis, enlarged accessibility to treatment, ramped up health expenditure into rare diseases, a supportive regulatory landscape, and escalated healthcare expenditure. The major forecast period trends include progression in orally administered treatments, embracement of gene therapy, technological progression within drug delivery systems, the employment of artificial intelligence within the evolution of SMA treatments, and gene manipulation technologies.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20965&type=smp

What Growth-Enabling Forces Are Impacting The Spinal Muscular Atrophy Market?

The escalating occurrence of rare genetic disorders is predicted to catalyze the expansion of the spinal muscular atrophy market in the future. These disorders are the result of gene mutations which impact a minor portion of the population, often leading to severe, long-lasting health issues. The amplified occurrence of rare genetic diseases is tied to enhanced diagnostic methods, heightened awareness, and increased access to genetic testing, thereby resulting in more instances being detected and reported. Spinal muscular atrophy (SMA) is a distinct rare genetic condition that epitomizes the difficulties and potential of comprehending inherited illnesses. It underscores the significance of progressing research into genetic disorders. For example, in July 2023, as per a report published by the Office for National Statistics, a UK-based government department, genetic testing of SMN1 has allowed for meticulous epidemiological studies, disclosing that SMA transpires in 1 out of 10,000 to 20,000 live births and over 95% of the impacted patients are homozygous for SMN1 deletion. Hence, the escalating occurrence of rare genetic disorders is projected to propel the growth of the spinal muscular atrophy market.

How Does The Spinal Muscular Atrophy Market Differ By Segment?

The spinal muscular atrophymarket covered in this report is segmented –

1) By Type: Type 1 (Severe); Type 2 (Intermediate); Type 3 (Mild); Type 4 (Adult)

2) By Age: Pediatric; Adults

3) By Treatment: Drug Therapy; Gene Therapy

4) By End User: Hospital pharmacy; Online pharmacy; Retail pharmacy

Subsegments:

1) By Type 1 (Severe): Infantile-Onset SMA; Severe Progressive SMA

2) By Type 2 (Intermediate): Early-Onset SMA; Non-progressive SMA

3) By Type 3 (Mild): Juvenile-Onset SMA; Mild Progressive SMA

4) By Type 4 (Adult): Adult-Onset SMA; Late-Onset SMA

What Are The Dominant Trends Currently Seen In The Spinal Muscular Atrophy Market?

Leading companies involved in the spinal muscular atrophy market are focusing on creating novel products like dry syrup, aimed at improving patient compliance and simplifying administration for pediatric populations and other patients who find swallowing hard. Dry syrup is a medication format that involves powder which is mixed with water prior to its use, usually prescribed to children and individuals who struggle with the ingestion of pills or capsules. For example, in September 2024, Chugai Pharmaceutical Co., Ltd., hailing from Japan, officially declared the receipt of regulatory acceptance from Japan’s Ministry of Health, Labour and Welfare to broaden the indication of their drug Evrysdi (risdiplam). This allowance facilitates its use in treating pre-symptomatic spinal muscular atrophy (SMA) and further enables dosage in infants younger than two months. This achievement is crucial as it allows treatments to commence before any symptoms even emerge, which potentially increases therapy results in affected children. The decision was verified by findings from the RAINBOWFISH study, which tested Evrysdi’s safety and effectiveness in babies diagnosed with SMA but not yet exhibiting symptoms. The results demonstrated treated infants accomplished developmental milestones like unaided sitting and enhanced motor abilities by their first year, highlighting the drug’s potential to alter the course of the disease when administered at an early stage.

Who Are The Most Influential Companies In The Spinal Muscular Atrophy Market?

Major companies operating in the spinal muscular atrophy market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Bayer AG, Novartis AG, Biogen Inc., Chugai Pharmaceutical Co. Ltd., Genentech Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Biohaven Ltd., Catalyst Pharmaceuticals Inc., RegenXBio Inc., Cytokinetics Inc., AveXis Inc., Scholar Rock Inc., Genethon, CANbridge Pharmaceuticals Inc., NMD Pharma A/S, Hanugen Therapeutics Inc., Beijing Jinlan Gene Technology Co. Ltd.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/spinal-muscular-atrophy-global-market-report

Which Region Is Leading Innovation In The Spinal Muscular Atrophy Market?

North America was the largest region in the spinal muscular atrophy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the spinal muscular atrophy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=20965&type=smp

Browse Through More Reports Similar to the Global Spinal Muscular Atrophy Market 2025, By The Business Research Company

Optic Atrophy Management Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/optic-atrophy-management-global-market-report

Spinal Surgery Devices And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/spinal-surgery-devices-and-equipment-global-market-report

Cerebrospinal Fluid Management Csf Devices And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cerebrospinal-fluid-management-csf-devices-and-equipment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Global Market Value Of The Spinal Muscular Atrophy Industry In 2025?

The spinal muscular atrophy market size has seen swift expansion in recent years. It is anticipated to increase from $3.53 billion in 2024 to $4 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 13.3%. This historical growth can be linked to several factors including increased diagnosis and early detection, the rising prevalence of rare genetic disease, advancements in healthcare infrastructure, support from government and regulatory bodies, and a growth in unmet healthcare needs.

The spinal muscular atrophy market is anticipated to experience substantial growth over the upcoming years, with projections indicating it will reach $6.53 billion by 2029, achieving a compound annual growth rate (CAGR) of 13.0%. This expansion during the forecast period is primarily driven by heightened awareness and improved diagnosis, increased access to treatments, greater healthcare investments targeting rare diseases, a supportive regulatory landscape, and rising healthcare expenditure. Notable trends emerging in this period involve progress in oral therapies, the increasing adoption of gene therapy, technological improvements in drug delivery systems, the integration of artificial intelligence into SMA treatment development, and advancements in gene editing technologies.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20965&type=smp

Which Drivers Are Supporting Growth Of The Spinal Muscular Atrophy Market?

The increasing occurrence of rare genetic diseases is anticipated to boost the expansion of the spinal muscular atrophy market moving forward. These conditions are disorders caused by genetic mutations, affecting a small segment of the population and often leading to severe, chronic health problems. The growing prevalence of rare genetic diseases can be attributed to advancements in diagnostic technologies, heightened awareness, and improved access to genetic testing, which results in more cases being identified and reported. Spinal muscular atrophy (SMA) is a rare genetic disorder that exemplifies both the difficulties and opportunities involved in understanding inherited diseases. It underscores the importance of advancing research into genetic conditions. For instance, in July 2023, as per a report published by the Office for National Statistics, a UK-based government department, genetic testing of SMN1 has enabled precise epidemiological studies, revealing that SMA occurs in 1 of 10,000 to 20,000 live births and that more than 95% of affected patients are homozygous for SMN1 deletion. Therefore, the rising prevalence of rare genetic diseases will stimulate the growth of the spinal muscular atrophy market.

What Are The Key Segments In The Spinal Muscular Atrophy Market?

The spinal muscular atrophymarket covered in this report is segmented –

1) By Type: Type 1 (Severe); Type 2 (Intermediate); Type 3 (Mild); Type 4 (Adult)

2) By Age: Pediatric; Adults

3) By Treatment: Drug Therapy; Gene Therapy

4) By End User: Hospital pharmacy; Online pharmacy; Retail pharmacy

Subsegments:

1) By Type 1 (Severe): Infantile-Onset SMA; Severe Progressive SMA

2) By Type 2 (Intermediate): Early-Onset SMA; Non-progressive SMA

3) By Type 3 (Mild): Juvenile-Onset SMA; Mild Progressive SMA

4) By Type 4 (Adult): Adult-Onset SMA; Late-Onset SMA

How Are Trends Influencing The Spinal Muscular Atrophy Market?

Major companies operating in the spinal muscular atrophy market are creating innovative products, such as dry syrup, to enhance medication adherence and ease of administration for pediatric and other patient groups who experience swallowing difficulties. Dry syrup is a powdered medication that requires reconstitution with water before use, frequently prescribed for children and individuals who struggle with swallowing tablets or capsules. For example, in September 2024, Chugai Pharmaceutical Co., Ltd., a pharmaceutical company based in Japan, announced that Japan’s Ministry of Health, Labour and Welfare had granted regulatory approval for an expanded indication of its drug Evrysdi (risdiplam). This approval permits its use in pre-symptomatic spinal muscular atrophy (SMA) and extends dosing to infants younger than two months old. This achievement is vital as it allows treatment to begin before symptoms emerge, potentially improving therapeutic outcomes for affected infants. The decision was supported by findings from the RAINBOWFISH study, which assessed Evrysdi’s safety and efficacy in infants diagnosed with SMA but not yet displaying symptoms. Results showed that treated infants reached developmental milestones, such as unsupported sitting and enhanced motor skills, by 12 months, emphasizing the drug’s potential to alter the disease’s progression when administered early.

Who Are The Core Companies Influencing The Spinal Muscular Atrophy Market Landscape?

Major companies operating in the spinal muscular atrophy market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Bayer AG, Novartis AG, Biogen Inc., Chugai Pharmaceutical Co. Ltd., Genentech Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Biohaven Ltd., Catalyst Pharmaceuticals Inc., RegenXBio Inc., Cytokinetics Inc., AveXis Inc., Scholar Rock Inc., Genethon, CANbridge Pharmaceuticals Inc., NMD Pharma A/S, Hanugen Therapeutics Inc., Beijing Jinlan Gene Technology Co. Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/spinal-muscular-atrophy-global-market-report

Which Geographies Are Emerging As Strong Markets For The Spinal Muscular Atrophy Industry?

North America was the largest region in the spinal muscular atrophy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the spinal muscular atrophy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Spinal Muscular Atrophy Market Report:

https://www.thebusinessresearchcompany.com/customise?id=20965&type=smp

Browse Through More Reports Similar to the Global Spinal Muscular Atrophy Market 2025, By The Business Research Company

Optic Atrophy Management Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/optic-atrophy-management-global-market-report

Spinal Surgery Devices And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/spinal-surgery-devices-and-equipment-global-market-report

Cerebrospinal Fluid Management Csf Devices And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cerebrospinal-fluid-management-csf-devices-and-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Spinal Muscular Atrophy Market Growth Performance Trended Historically, And What Lies Ahead?

In recent years, we have observed a brisk expansion in the spinal muscular atrophy market size. From $3.53 billion in 2024, it is expected to scale up to $4 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 13.3%. The notable growth during the previous period is a result of factors such as enhanced diagnostic capabilities and early detection, rising incidences of rare genetic diseases, improvements in healthcare infrastructure, support from government and regulatory bodies, and a surge in unfulfilled healthcare needs.

The market for spinal muscular atrophy is predicted to experience swift expansion in the coming years, ballooning to$6.53 billion by 2029″ at a CAGR of 13.0%. The anticipated growth in this period can be credited to elements such as heightened awareness and diagnosis level, broadening treatment opportunities, an increase in health care investments in rare diseases, a supportive regulatory atmosphere, and a rise in health care expenditure. Key trends during this forecast period are expected to be the evolution in oral treatments, acceptance of gene therapy, advancements in drug delivery systems, the integration of artificial intelligence in the development of SMA treatments, and advancements in gene editing technologies.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20965&type=smp

How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theSpinal Muscular Atrophy Market?

The increase in rare genetic diseases is anticipated to boost the spinal muscular atrophy market in the future. These rare genetic diseases, which are caused by gene mutations and impact a tiny proportion of the population, often lead to serious, long-term health issues. The heightened incidence of such diseases is due to advancements in diagnostic techniques, greater awareness, and easier access to genetic testing, contributing to more cases being discovered and reported. Spinal muscular atrophy (SMA) provides a clear example of the issues and potential in learning about hereditary diseases, underlining the need to further research into genetic conditions. For example, a report from the Office for National Statistics, a United Kingdom government agency, in July 2023, indicated that SMN1 genetic testing has facilitated accurate epidemiological studies. These studies revealed that SMA appears in 1 of every 10,000 to 20,000 live births and that over 95% of the patients afflicted are homozygous for SMN1 deletion. As a result, the increasing prevalence of rare genetic diseases is expected to fuel the growth of the spinal muscular atrophy market.

Which Segments in the Spinal Muscular Atrophy Offer the Most Growth?

The spinal muscular atrophymarket covered in this report is segmented –

1) By Type: Type 1 (Severe); Type 2 (Intermediate); Type 3 (Mild); Type 4 (Adult)

2) By Age: Pediatric; Adults

3) By Treatment: Drug Therapy; Gene Therapy

4) By End User: Hospital pharmacy; Online pharmacy; Retail pharmacy

Subsegments:

1) By Type 1 (Severe): Infantile-Onset SMA; Severe Progressive SMA

2) By Type 2 (Intermediate): Early-Onset SMA; Non-progressive SMA

3) By Type 3 (Mild): Juvenile-Onset SMA; Mild Progressive SMA

4) By Type 4 (Adult): Adult-Onset SMA; Late-Onset SMA

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=20965&type=smp

What Are the Fastest-Growing Geographies in the #How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theSpinal Muscular Atrophy Market?# Market?

North America was the largest region in the spinal muscular atrophy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the spinal muscular atrophy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Current Market Growth and Trends in the Spinal Muscular Atrophy Industry?

Several large firms in the spinal muscular atrophy market are creating unique products like dry syrup to boost medication adherence and make administering medicine easier for pediatric patients and others facing difficulties swallowing. Dry syrup, a medicinal powder that is mixed with water before ingestion, is usually given to children and patients who struggle to swallow tablets or capsules. For example, in September 2024, Japan’s Chugai Pharmaceutical Co., Ltd. attained regulatory approval from the Ministry of Health, Labour and Welfare of Japan for the extended use of its drug, Evrysdi (risdiplam). The approval enables its administration to pre-symptomatic spinal muscular atrophy (SMA) patients and those under two months of age. This crucial step allows for earlier treatment before the onset of symptoms, possibly improving the therapeutic results for affected infants. The decision was backed by the RAINBOWFISH study data, which evaluated Evrysdi’s safety and effectiveness in SMA-diagnosed infants not yet showing symptoms. Results revealed that infants treated with Evrysdi reached developmental milestones like unaided sitting and enhanced motor skills within 12 months. This highlights the potential of the drug to alter the course of the disease if given early.

View the full report here:

https://www.thebusinessresearchcompany.com/report/spinal-muscular-atrophy-global-market-report

What Are the Key Elements That Define the Spinal Muscular Atrophy Market?

Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder characterized by the progressive loss of motor neurons in the spinal cord, leading to muscle weakness and atrophy. It is caused by mutations in the SMN1 gene, resulting in insufficient survival motor neuron (SMN) protein. SMA affects voluntary muscle movements, particularly those involved in walking, swallowing, and breathing.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20965

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Spinal Muscular Atrophy Market?

In the last few years, the spinal muscular atrophy market has seen significant growth. It is projected to expand from $3.53 billion in 2024 to $4.01 billion in 2025, with a compound annual growth rate (CAGR) of 13.5%. The surge during the past period has been driven by factors such as escalated diagnosis and early detection, rising incidences of uncommon genetic diseases, enhanced healthcare infrastructure, government and regulatory backing, as well as an upswing in unresolved healthcare requirements.

What Growth Rate Is Forecasted for the Spinal Muscular Atrophy Market by 2029?

There is anticipated rapid expansion in the spinal muscular atrophy market in the ensuing years. It is projected to reach $6.59 billion in 2029, with a compound annual growth rate (CAGR) of 13.2%. Factors contributing to this growth in the forecast period include enhanced awareness and diagnosis, wider access to treatment, an increase in healthcare investments that target rare diseases, a conducive regulatory environment, and escalating healthcare expenditure. Noteworthy trends in the anticipated period comprise breakthroughs in oral therapies, the utilization of gene therapy, advances in technologies for drug delivery systems, the use of artificial intelligence in the development of SMA treatments, and cutting-edge gene editing technologies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20965&type=smp

Which Key Companies Are Shaping the Future of the Spinal Muscular Atrophy Market?

Major companies operating in the spinal muscular atrophy market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Bayer AG, Novartis AG, Biogen Inc., Chugai Pharmaceutical Co. Ltd., Genentech Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Biohaven Ltd., Catalyst Pharmaceuticals Inc., RegenXBio Inc., Cytokinetics Inc., AveXis Inc., Scholar Rock Inc., Genethon, CANbridge Pharmaceuticals Inc., NMD Pharma A/S, Hanugen Therapeutics Inc., Beijing Jinlan Gene Technology Co. Ltd.

Which Factors Are Driving Demand in the Spinal Muscular Atrophy Industry?

The growth of the spinal muscular atrophy market is anticipated to be accelerated by the escalating rates of rare genetic disorders. These genetic disorders, which affect a small portion of the overall population, are born out of mutated genes and often lead to intense, chronic health issues. Upgraded diagnostic technologies, heightened public consciousness, and enhanced access to genetic testing have all contributed to the increase in recognized and reported cases of rare genetic disorders. Spinal muscular atrophy (SMA), a peculiar genetic disorder, epitomizes the difficulties and possibilities of comprehending inherited maladies, highlighting the urgency of progressing genetic condition-related research. For example, in July 2023, a study by the Office for National Statistics, a governmental department in the UK, made it known that genetic testing of SMN1 has paved the way for exact epidemiological studies. It confirmed that SMA is found in 1 in 10,000 to 20,000 live births, with over 95% of patients affected being homozygous for SMN1 deletion. Consequently, the increasing rates of rare genetic disorders are set to stimulate the expansion of the spinal muscular atrophy market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=20965&type=smp

How Is the Spinal Muscular Atrophy Market Segmented by Several Divisions?

The spinal muscular atrophy market covered in this report is segmented –

1) By Type: Type 1 (Severe), Type 2 (Intermediate), Type 3 (Mild), Type 4 (Adult)

2) By Age: Pediatric, Adults

3) By Treatment: Drug Therapy, Gene Therapy

4) By End User: Hospital pharmacy, Online pharmacy, Retail pharmacy

Subsegments:

1) By Type 1 (Severe): Infantile-Onset SMA, Severe Progressive SMA

2) By Type 2 (Intermediate): Early-Onset SMA, Non-progressive SMA

3) By Type 3 (Mild): Juvenile-Onset SMA, Mild Progressive SMA

4) By Type 4 (Adult): Adult-Onset SMA, Late-Onset SMA

What are the Emerging Market Trends Driving the Growth of the Spinal Muscular Atrophy Industry?

Leading firms in the spinal muscular atrophy market are advancing their product offerings by developing unique solutions like dry syrup. This innovation aims to aid medication compliance and simplify administration for pediatric patients and other groups who experience difficulty swallowing. Dry syrup, a medication in powdered form, is mixed with water prior to consumption and is usually prescribed for children and patients who struggle with intaking tablets or capsules. Chugai Pharmaceutical Co., Ltd., a pharmaceutical organization based in Japan, reported in September 2024 that it had received regulatory approval from the nation’s Ministry of Health, Labour and Welfare for widened usage of their drug, Evrysdi (risdiplam). The approval allows Evrysdi to be used in pre-symptomatic spinal muscular atrophy (SMA) and expands dosing to infants younger than two months. This development is significant as it allows treatment to start before symptoms manifest, potentially improving therapeutic results in affected infants. The decision was backed by the RAINBOWFISH study’s findings, which evaluated the safety and efficacy of Evrysdi in infants diagnosed with SMA but not yet showing symptoms. The results demonstrated that infants treated with the drug reached developmental milestones including unsupported sitting and better motor skills within 12 months, pointing to the drug’s capacity to alter the course of the disease when administered promptly.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/spinal-muscular-atrophy-global-market-report

Which Regions Are Driving Growth in the Spinal Muscular Atrophy Market?

North America was the largest region in the spinal muscular atrophy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the spinal muscular atrophy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20965

This Report Delivers Insight On:

1. How big is the spinal muscular atrophy market, and how is it changing globally?

2. Who are the major companies in the spinal muscular atrophy market, and how are they performing?

3. What are the key opportunities and risks in the spinal muscular atrophy market right now?

4. Which products or customer segments are growing the most in the spinal muscular atrophy market?

5. What factors are helping or slowing down the growth of the spinal muscular atrophy market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

What is the Projected CAGR for the Spinal Muscular Atrophy Market Size from 2025 to 2034?

The market for spinal muscular atrophy has experienced swift expansion in recent times. Its growth is projected to increase from $3.53 billion in 2024 to $4.01 billion in 2025, marking a compound annual growth rate (CAGR) of 13.5%. The notable growth during the historical period is due to factors such as enhanced diagnosis and early detection efforts, an increasing occurrence of rare genetic diseases, advancements in healthcare infrastructure, support from government and regulatory bodies, and the rise in unfulfilled healthcare requirements.

Anticipated in the coming years is a swift upsurge in the market size of spinal muscular atrophy. A compound annual growth rate (CAGR) of 13.2% is forecasted, propelling the market to reach $6.59 billion by 2029. The projected growth within this period can be credited to factors like enhanced awareness and diagnosis rates, improved accessibility of treatment, rising investments in healthcare regarding rare diseases, a conducive regulatory climate, and escalating healthcare expenditure. Key trends predicted for the forecast period involve progress in oral therapies, the application of gene therapy, advancements in drug delivery technology, the incorporation of artificial intelligence in the development of SMA treatment, and gene editing technologies.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20965&type=smp

What Are the Core Growth Drivers Propelling the Spinal Muscular Atrophy Market Forward?

The growth of the spinal muscular atrophy market is set to be largely influenced by the increased occurrence of uncommon genetic illnesses. These disorders, which only affect a small demographic due to gene mutations, often lead to significant, ongoing health challenges. The upsurge in the occurrence of such rare genetic conditions can be linked to enhanced diagnostic tools, a greater public consciousness, and easier access to genetic testing, which contribute to an increased number of diagnosed and reported cases. Spinal muscular atrophy (SMA) represents an example of the complexities and potential associated with understanding inherited diseases. Furthering the investigation into genetic disorders is therefore of vital importance. For instance, a report from the Office for National Statistics, a UK government department, reveals that as of July 2023, SMA, which affects between 1 in 10,000 and 20,000 live births with over 95% of sufferers being homozygous for SMN1 deletion, has been precisely recorded due to genetic testing of the SMN1 gene. As such, the increasing occurrence of rare genetic conditions is set to fuel the growth of the spinal muscular atrophy market.

What Segment Types Define the Spinal Muscular Atrophy Market Structure?

The spinal muscular atrophy market covered in this report is segmented –

1) By Type: Type 1 (Severe), Type 2 (Intermediate), Type 3 (Mild), Type 4 (Adult)

2) By Age: Pediatric, Adults

3) By Treatment: Drug Therapy, Gene Therapy

4) By End User: Hospital pharmacy, Online pharmacy, Retail pharmacy

Subsegments:

1) By Type 1 (Severe): Infantile-Onset SMA, Severe Progressive SMA

2) By Type 2 (Intermediate): Early-Onset SMA, Non-progressive SMA

3) By Type 3 (Mild): Juvenile-Onset SMA, Mild Progressive SMA

4) By Type 4 (Adult): Adult-Onset SMA, Late-Onset SMA

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=20965&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Spinal Muscular Atrophy Market?

North America was the largest region in the spinal muscular atrophy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the spinal muscular atrophy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Market Trends and Innovations Are Shaping the Future of the Spinal Muscular Atrophy Industry?

Notable businesses in the spinal muscular atrophy industry are working on the creation of novel items like dry syrup to provide better medication adherence and simplify administration for pediatric patients and others who find it challenging to swallow. Dry syrup refers to a powdery drug that is blended with water prior to consumption. This medication is primarily prescribed to infants and patients having trouble swallowing pills or capsules. In September 2024, for example, the Japan-centric pharmaceutical firm Chugai Pharmaceutical Co., Ltd. received authorization from the Ministry of Health, Labour and Welfare of Japan for its expanded drug indication, Evrysdi (risdiplam). This approval makes it possible for the drug to be used in unsymptomatic spinal muscular atrophy (SMA) cases and permits dosage to infants under two months old. This key development allows the commencement of treatment before the manifestation of symptoms, potentially boosting therapeutic results for affected babies. The approval was backed by findings from the RAINBOWFISH research which evaluated the safety and effectiveness of Evrysdi in infants diagnosed with SMA who do not have symptoms yet. Results indicated that the infants who received the treatment reached developmental milestones such as unsupported sitting and enhanced motor abilities by 12 months. This emphasizes the drug’s potential to alter the progression of this disease if given early.

View the full report here:

https://www.thebusinessresearchcompany.com/report/spinal-muscular-atrophy-global-market-report

What Is the Definition of the Spinal Muscular Atrophy Market?

Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder characterized by the progressive loss of motor neurons in the spinal cord, leading to muscle weakness and atrophy. It is caused by mutations in the SMN1 gene, resulting in insufficient survival motor neuron (SMN) protein. SMA affects voluntary muscle movements, particularly those involved in walking, swallowing, and breathing.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20965

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Factors Are Propelling the Market Growth of theSpinal Muscular Atrophy Market from 2025 to 2034?

The spinal muscular atrophy market’s growth is anticipated to be fueled by the mounting occurrence of unique genetic disorders. These rare genetic conditions, caused by gene mutations and impacting a tiny portion of the population, frequently result in serious and prolonged health issues. Better diagnostic tools, a heightened awareness, and broader access to genetic testing, have led to the increase in the identification and reporting of unique genetic disorders. Spinal muscular atrophy (SMA), a rare genetic disease, best demonstrates the complexities and possibilities related to comprehending inherited diseases. It underlines the need to accelerate research into these genetic conditions. An example is a report published in July 2023, by the UK’s Office for National Statistics, which indicated that genetic testing of SMN1 helps facilitate accurate epidemiological studies. This has shown that SMA occurs in every 10,000 to 20,000 live births and over 95% of affected patients are homozygous for the SMN1 deletion. As such, the escalation in occurrences of rare genetic diseases is expected to trigger the growth of the spinal muscular atrophy market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20965&type=smp

#What is the Projected CAGR for the Spinal Muscular Atrophy Market Size from 2025 to 2034?

In recent times, the spinal muscular atrophy market has witnessed swift expansion. By 2025, it is projected to inflate from its 2024 value of $3.53 billion to $4.01 billion, with a compound annual growth rate (CAGR) of 13.5%. Factors such as enhanced diagnosis and early detection capabilities, rising incidence of rare genetic disorders, upgrade in healthcare infrastructure and supportive government and regulatory assistance, as well as the surge in unaddressed healthcare requirements can be credited for the growth observed in the historic period.

In the upcoming years, the market size for spinal muscular atrophy is projected to experience significant expansion, growing to a value of $6.59 billion by 2029 at a compound annual growth rate of 13.2%. The growth anticipated in the forecast period can be credited to factors such as rising awareness and diagnosis, broader access to treatment, enhanced healthcare investment in uncommon diseases, a supportive regulatory framework, and escalating healthcare spending. Key trends that will characterize the forecast period encompass breakthroughs in oral therapies, embracing gene therapy, technologically advanced drug delivery systems, the incorporation of artificial intelligence in SMA treatment research, and gene editing technologies.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20965

How Are Market Trends and Innovations Revolutionizing theSpinal Muscular Atrophy Industry in Recent Times?

Leading firms in the spinal muscular atrophy market are spearheading the development of groundbreaking products like dry syrup. This innovation is aimed at bolstering medicine compliance and easing administration for pediatric patients and others struggling with swallowing difficulties. Dry syrup, a reconstitutable powdered remedy, is often recommended for individuals who find it challenging to ingest pills or capsules. Chugai Pharmaceutical Co., Ltd, based out of Japan, announced in September 2024 that they had received regulatory approval from the nation’s Ministry of Health, Labour and Welfare to widen the indications of their drug, Evrysdi (risdiplam). This approval has permitted the use of the drug in pre-symptomatic spinal muscular atrophy (SMA) cases and extended the dosage to include infants below two months. This significant progression allows treatments to commence before the onset of any symptoms that could potentially enhance therapy outcomes for the affected infants. The decision was backed up by the results from the RAINBOWFISH study which evaluated the drug’s safety and effectiveness in infants diagnosed with SMA but are not yet symptomatic. The study demonstrated that infants treated with the drug hit developmental milestones like unsupported sitting and enhanced motor skills by 12 months, underlining the drug’s potential to alter the course of the disease when administered early.

Which Key Market Players Are Shaping the Future and Growth of theSpinal Muscular Atrophy Market?

Major companies operating in the spinal muscular atrophy market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Bayer AG, Novartis AG, Biogen Inc., Chugai Pharmaceutical Co. Ltd., Genentech Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Biohaven Ltd., Catalyst Pharmaceuticals Inc., RegenXBio Inc., Cytokinetics Inc., AveXis Inc., Scholar Rock Inc., Genethon, CANbridge Pharmaceuticals Inc., NMD Pharma A/S, Hanugen Therapeutics Inc., Beijing Jinlan Gene Technology Co. Ltd.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/spinal-muscular-atrophy-global-market-report

What Are the Core Segments of the Spinal Muscular Atrophy Market, and How Do They Contribute to Growth?

The spinal muscular atrophy market covered in this report is segmented –

1) By Type: Type 1 (Severe), Type 2 (Intermediate), Type 3 (Mild), Type 4 (Adult)

2) By Age: Pediatric, Adults

3) By Treatment: Drug Therapy, Gene Therapy

4) By End User: Hospital pharmacy, Online pharmacy, Retail pharmacy

Subsegments:

1) By Type 1 (Severe): Infantile-Onset SMA, Severe Progressive SMA

2) By Type 2 (Intermediate): Early-Onset SMA, Non-progressive SMA

3) By Type 3 (Mild): Juvenile-Onset SMA, Mild Progressive SMA

4) By Type 4 (Adult): Adult-Onset SMA, Late-Onset SMA

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=20965&type=smp

What Regions Are Dominating the Spinal Muscular Atrophy Market Growth?

North America was the largest region in the spinal muscular atrophy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the spinal muscular atrophy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Spinal Muscular Atrophy Market 2025, By The Business Research Company:

Optic Atrophy Management Global Market Report 2025

https://thebusinessresearchcompany.com/report/optic-atrophy-management-global-market-report

Spinal Surgery Devices And Equipment Global Market Report 2025

https://thebusinessresearchcompany.com/report/spinal-surgery-devices-and-equipment-global-market-report

Cerebrospinal Fluid Management CSF Devices And Equipment Global Global Market Report 2025

https://thebusinessresearchcompany.com/report/cerebrospinal-fluid-management-csf-devices-and-equipment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the spinal muscular atrophy market grown over the years?

In recent times, a swift expansion has been observed in the market size for spinal muscular atrophy. The growth projection indicates that it will increase from $3.53 billion in 2024 to hit $4.01 billion in 2025, marking the compound annual growth rate (CAGR) at 13.5%. Factors such as heightened diagnosis and early detection rates, a rising prevalence of rare genetic diseases, enhancements in healthcare facilities, support from governmental and regulatory bodies, as well as a boost in unresolved healthcare necessities, have all contributed to this substantial growth in the historical timeframe.

What Is the forecasted market size and growth rate for the spinal muscular atrophy market?

The market for spinal muscular atrophy is poised for significant expansion in the coming years, projecting to reach $6.59 billion by 2029, with a compound annual growth rate (CAGR) of 13.2%. The anticipated growth during the forecast period can be ascribed to factors such as increased awareness and diagnosis, improvement in treatment accessibility, a surge in healthcare investments towards rare diseases, a conducive regulatory environment, and escalating healthcare spending. Key trends expected to influence the market during the forecast period include progress in oral therapies, embrace of gene therapy, technological breakthroughs in drug delivery systems, the application of artificial intelligence in the development of SMA treatments, and emerging gene editing technologies.

Get your spinal muscular atrophy market report here!

https://www.thebusinessresearchcompany.com/report/spinal-muscular-atrophy-global-market-report

What are the major factors driving growth in the spinal muscular atrophy market?

The growth of the spinal muscular atrophy market is anticipated to be stimulated by the surging incidence of uncommon genetic diseases. Such conditions are the result of aberrations in the genes, affecting a small segment of the population and often leading to grave, persistent health issues. The escalating incidence can be ascribed to refined diagnostic tools, heightened awareness, and better access to genetic screenings, consequently identifying and reporting more cases. Spinal muscular atrophy (SMA), an unusual genetic condition, epitomizes the complexities and possibilities inherent in understanding hereditary diseases, and emphasizes the need for advancing research in the area of genetics. For example, a report issued by the Office for National Statistics, a UK governmental department, in July 2023 conveyed that SMN1 genetic testing has facilitated precise epidemiological studies. These studies illustrate that SMA affects 1 in every 10,000 to 20,000 live births, and over 95% of affected individuals are homozygous for SMN1 deletion. Consequently, the mounting incidence of rare genetic conditions will catalyze the expansion of the spinal muscular atrophy market.

What key areas define the segmentation of the global spinal muscular atrophy Market?

The spinal muscular atrophy market covered in this report is segmented –

1) By Type: Type 1 (Severe), Type 2 (Intermediate), Type 3 (Mild), Type 4 (Adult)

2) By Age: Pediatric, Adults

3) By Treatment: Drug Therapy, Gene Therapy

4) By End User: Hospital pharmacy, Online pharmacy, Retail pharmacy

Subsegments:

1) By Type 1 (Severe): Infantile-Onset SMA, Severe Progressive SMA

2) By Type 2 (Intermediate): Early-Onset SMA, Non-progressive SMA

3) By Type 3 (Mild): Juvenile-Onset SMA, Mild Progressive SMA

4) By Type 4 (Adult): Adult-Onset SMA, Late-Onset SMA

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20965&type=smp

What are the top market players propelling the growth of the spinal muscular atrophy industry?

Major companies operating in the spinal muscular atrophy market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Bayer AG, Novartis AG, Biogen Inc., Chugai Pharmaceutical Co. Ltd., Genentech Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Biohaven Ltd., Catalyst Pharmaceuticals Inc., RegenXBio Inc., Cytokinetics Inc., AveXis Inc., Scholar Rock Inc., Genethon, CANbridge Pharmaceuticals Inc., NMD Pharma A/S, Hanugen Therapeutics Inc., Beijing Jinlan Gene Technology Co. Ltd.

What key trends are currently impacting the spinal muscular atrophy market’s development?

Major companies operating in the spinal muscular atrophy market are developing innovative products, such as dry syrup, to improve medication adherence and ease of administration for pediatric and other patient groups with swallowing difficulties. Dry syrup is a powdered medication that is reconstituted with water before use, commonly prescribed for children and patients who have difficulty swallowing tablets or capsules. For instance, in September 2024, Chugai Pharmaceutical Co., Ltd., a Japan-based pharmaceutical company, announced regulatory approval from Japan’s Ministry of Health, Labour and Welfare for an expanded indication of its drug Evrysdi (risdiplam). The approval allows its use in pre-symptomatic spinal muscular atrophy (SMA) and extends dosing to infants under two months old. This milestone is crucial as it enables treatment initiation before symptoms appear, potentially enhancing therapeutic outcomes for affected infants. The decision was supported by data from the RAINBOWFISH study, which assessed Evrysdi’s safety and efficacy in infants diagnosed with SMA but not yet symptomatic. Findings showed that treated infants achieved developmental milestones, such as unsupported sitting and improved motor skills, by 12 months, underscoring the drug’s potential to transform the disease’s progression when administered early.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20965

What regions are dominating the spinal muscular atrophy market growth?

North America was the largest region in the spinal muscular atrophy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the spinal muscular atrophy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Optic Atrophy Management Global Market Report 2025

https://thebusinessresearchcompany.com/report/optic-atrophy-management-global-market-report

Spinal Surgery Devices And Equipment Global Market Report 2025

https://thebusinessresearchcompany.com/report/spinal-surgery-devices-and-equipment-global-market-report

Cerebrospinal Fluid Management CSF Devices And Equipment Global Global Market Report 2025

https://thebusinessresearchcompany.com/report/cerebrospinal-fluid-management-csf-devices-and-equipment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: